<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-108 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-108</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-108</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <p><strong>Paper ID:</strong> paper-05596ed5781efe7d4de1ea19db563714ef01d871</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/05596ed5781efe7d4de1ea19db563714ef01d871" target="_blank">Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution</a></p>
                <p><strong>Paper Venue:</strong> Cell</p>
                <p><strong>Paper TL;DR:</strong> It is found that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity.</p>
                <p><strong>Cost:</strong> 0.018</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e108.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e108.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HLA LOH</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Allele-specific loss of heterozygosity at HLA class I locus (HLA-A, -B, -C)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Focal, allele-specific copy-number loss of one HLA class I haplotype (resulting in effective homozygosity) that reduces presentation of neoantigens and enables immune escape in non-small-cell lung cancer, including lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome sequencing (multi-region), allele-specific copy-number analysis using LOHHLA, phylogenetic mapping, neoantigen prediction, PD-L1 IHC, TCGA RNA-seq analysis</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>TRACERx multi-region cohort: 90 NSCLC patients analyzed by LOHHLA (59 lung adenocarcinomas, 31 lung squamous cell carcinomas); validation/extension in TCGA: 383 LUAD and 309 LUSC. Percentage of driver‑negative cases not specified in the study.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Allele-specific HLA loss (HLA LOH) as an immune‑escape driver enabling subclonal expansion</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic copy-number alteration (allele-specific focal deletion leading to LOH)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Observed HLA LOH in 36/90 (40%) NSCLCs overall (17/59 adenocarcinomas = ~29%); many events were subclonal and focal, enriched at metastatic sites, occurred in parallel on different branches (convergent evolution), were associated with increased subclonal non-synonymous mutation and neoantigen burdens, and neoantigens were enriched for those predicted to bind the lost allele. HLA LOH correlated with signatures of immune activation (elevated cytolytic score, PD-L1 positivity on immune cells) consistent with selection by an active immune microenvironment.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Not universal — many tumors lack HLA LOH; no homozygous deletions of HLA were observed (suggests a single allele is retained, likely to avoid NK cell killing). Association strength varies by histology (weaker in LUSC for some measures). HLA mutations and B2M mutations were rare in this cohort (HLA nonsynonymous mutations in 3 patients; single B2M mutation), indicating diverse mechanisms of antigen-presentation disruption beyond LOH.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Accumulation of (subclonal) neoantigens in an immune‑active microenvironment exerts selection for subclones that lose one HLA haplotype; these HLA-LOH subclones evade CD8+ T cell recognition allowing clonal/subclonal expansions and facilitating metastatic progression or therapy resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>McGranahan N, Rosenthal R, Hiley CT, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259-1271. doi:10.1016/j.cell.2017.10.001</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e108.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e108.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>APOBEC signatures</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>APOBEC-mediated mutagenesis (COSMIC Signatures 2 and 13)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Activity of APOBEC cytidine deaminases leaving specific somatic mutation signatures (2 and 13) that contribute to subclonal mutational burden and are associated with HLA LOH in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Mutational-signature analysis from whole-exome sequencing (deconstructSigs)</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>TRACERx NSCLC cohort (same as above); signature analyses stratified by histology (LUAD vs LUSC). Percentage of driver‑negative cases not specified.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>APOBEC-mediated mutagenic process as a contributor to elevated subclonal mutation/neoantigen burden driving selection for immune-escape events (e.g., HLA LOH)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Mutational process / genetic (endogenous enzymatic mutagenesis)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Lung adenocarcinomas with any HLA LOH showed a significant increase in APOBEC-related mutational signatures (Signatures 2 and 13) (NSCLC p = 0.03; LUAD p = 0.003), suggesting APOBEC activity contributes to the subclonal mutation load that may drive immune selection for HLA LOH.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>No differential contribution of other mutational signatures (1A, 4, 5) was observed; the association was strong in adenocarcinoma but not significant in squamous cell carcinoma (LUSC p = 0.63), indicating subtype specificity and that APOBEC is not the only route to high subclonal burden.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Heightened APOBEC activity produces many subclonal neoantigens that increase immune predation, thereby selecting for subclones that evade presentation (e.g., via HLA LOH).</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>McGranahan N, Rosenthal R, Hiley CT, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259-1271. doi:10.1016/j.cell.2017.10.001</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e108.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e108.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PD-L1 / IFN-γ immune activation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PD-L1 upregulation and interferon-γ (IFN-γ)–associated cytolytic immune activation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor and immune-cell PD-L1 expression and IFN-γ / cytolytic gene-expression signatures that reflect an active immune microenvironment and are associated with HLA LOH, implying microenvironmental selection pressure for immune escape.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Immunohistochemistry (PD-L1 on tumor and immune cells), TCGA RNA-seq immune-signature analyses (cytolytic activity, CD8+ T cell abundance, NK cell abundance)</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>TRACERx diagnostic FFPE IHC on subset; TCGA validation: 383 LUAD and 309 LUSC for RNA-seq based immune measures. Percentage of driver‑negative cases not specified.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Active antitumor immune microenvironment (PD-L1 expression, IFN-γ signaling, cytolytic activity) acting as a selection force promoting immune-escape alterations such as HLA LOH</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Microenvironmental / immunological selection pressure</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Tumors with clonal HLA LOH had significantly increased PD-L1 staining on immune cells (p = 0.029) and trends for tumor-cell PD-L1; TCGA analyses showed elevated cytolytic activity (GZMA + PRF1), increased CD8+ T cell and NK cell abundance, upregulation of PD-L1 and IFN-γ–associated genes in LUAD with HLA LOH, consistent with an immune‑active environment selecting for antigen-presentation loss.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Association patterns differed by histology (some immune signatures increased in LUAD but not LUSC). Correlation does not prove causation — immune activation may be consequence rather than cause in some contexts. HLA LOH may also occur via genomic instability independent of immune selection, although focality and parallel evolution argue for selection.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>An immune‑predatory microenvironment (CD8+ T cells, IFN-γ, PD-L1 induction) creates local selective pressure favoring subclones that lose HLA alleles and thereby avoid T cell recognition.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>McGranahan N, Rosenthal R, Hiley CT, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259-1271. doi:10.1016/j.cell.2017.10.001</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e108.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e108.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>B2M mutation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>β-2 microglobulin (B2M) mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mutation of B2M, a gene required for MHC class I surface expression/stability, can disrupt antigen presentation and enable immune escape; observed as a rare event in the cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome sequencing (mutation calling with POLYSOLVER/VarScan/MuTect)</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>TRACERx cohort (90 NSCLCs); a single lung adenocarcinoma in the cohort had an acquired B2M mutation. Percentage of driver‑negative cases not specified.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Loss-of-function mutation in B2M leading to defective MHC class I antigen presentation and immune evasion</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic mutation (loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>One tumor in the TRACERx cohort acquired a B2M mutation, consistent with previous reports (del Campo et al., 2014) that B2M loss can mediate immune escape; the paper notes B2M mutations as an alternative mechanism to HLA LOH for disrupting antigen presentation.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Extremely infrequent in this dataset (only one case), so B2M mutation is not a common driver in this cohort; the rarity limits its contribution compared to HLA LOH. No systematic functional validation in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Tumors can evade CD8+ T cell recognition by losing B2M, thereby abolishing stable MHC class I surface expression, as an alternative to allele‑specific HLA loss.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>McGranahan N, Rosenthal R, Hiley CT, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259-1271. doi:10.1016/j.cell.2017.10.001</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e108.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e108.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NLRC5 disruption (mentioned)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NLRC5 (MHC class I transactivator) downregulation or inactivation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>NLRC5 is a transcriptional regulator of MHC class I expression; its disruption has been proposed as an immune-evasion mechanism that reduces antigen presentation (cited here as a potential alternative to HLA LOH).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>NLRC5/MHC class I transactivator is a target for immune evasion in cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Mentioned (prior literature) — not directly analyzed functionally in this study</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Not tested directly in TRACERx cohort within this paper; mentioned as an alternative mechanism based on prior publications.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Transcriptional or genetic targeting of NLRC5 leading to reduced MHC class I expression and immune escape</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic / transcriptional regulator (epigenetic or expression-level alteration)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>NLRC5 is cited (Yoshihama et al., 2016) as a target for immune evasion in cancer; the present paper discusses NLRC5 as one possible mechanism to disrupt antigen presentation in tumors that do not show HLA LOH or B2M/HLA mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>This paper provides no direct NLRC5 data; NLRC5 disruption remains a proposed mechanism requiring further validation in lung adenocarcinoma datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Downregulation or mutation of NLRC5 reduces MHC class I expression, providing an alternative immune-escape route to HLA LOH in tumors under immune selection.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Yoshihama S, Roszik J, Downs I, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016;113:5999-6004.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e108.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e108.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Subclonal neoantigen enrichment</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Enrichment of subclonal neoantigens predicted to bind the lost HLA haplotype</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor subclones that underwent HLA LOH are enriched for subclonal neoantigens predicted to bind the now-lost allele — consistent with immune editing selecting against presentation of these neoantigens.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Neoantigen prediction from exome data (netMHCpan/netMHC), clonal/subclonal mutation mapping from multi-region sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>TRACERx cohort: analysis focused on tumors with six distinct HLA alleles and a haplotype loss in at least one region (n = 20 for the specific analysis), broader cohort of 36 patients with HLA LOH used for global analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Immune editing by CD8+ T cells acting on subclonal neoantigens drives selection for HLA LOH; enriched subclonal neoantigens (binding lost alleles) provide the selective pressure.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Microevolutionary mechanism (immune editing) driven by genetic neoantigen load</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Paired analyses showed significant enrichment of subclonal neoantigens predicted to bind lost HLA alleles compared to kept alleles (NSCLC p = 0.0083), and subclones with HLA LOH had higher non-synonymous mutation and neoantigen burdens than sister subclones without LOH. One tumor had up to 92% of predicted neoantigens binding the lost haplotype.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Not all tumors with high neoantigen burden show HLA LOH; some tumors (especially LUSC) may use other evasion strategies. Neoantigen binding predictions are computational and were not functionally validated for presentation or T cell recognition in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Subclonal accumulation of neoantigens that are effectively presented by a specific HLA haplotype results in immune selection against cells expressing that haplotype, leading to focal LOH of that haplotype and outgrowth of escape subclones.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>McGranahan N, Rosenthal R, Hiley CT, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259-1271. doi:10.1016/j.cell.2017.10.001</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution', 'publication_date_yy_mm': '2017-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes <em>(Rating: 2)</em></li>
                <li>T-cell transfer therapy targeting mutant KRAS in cancer <em>(Rating: 2)</em></li>
                <li>Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets <em>(Rating: 2)</em></li>
                <li>NLRC5/MHC class I transactivator is a target for immune evasion in cancer <em>(Rating: 2)</em></li>
                <li>Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma <em>(Rating: 1)</em></li>
                <li>Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>